3rd Jul 2014 08:25
LONDON (Alliance News) - Summit Corporation PLC said Thursday that the first patients have been dosed in its Phase II proof of concept trial of its SMT19969 antibiotic for the treatment of C. difficile infection.
C. difficile bacteria infects the colon, causing serious illness, and is typically contracted by patients being treated with antibiotics which disrupt the normal gut flora. Existing antibiotics to handle the infection cause further damage to the gut, which can lead to high rates of recurrent disease.
The trial is begin supported by an award from British medical research foundation the Wellcome Trust.
On Wednesday UK Prime Minister David Cameron announced a review into why so few anti-microbial drugs have been introduced in recent years, as concerns grow over the rising number of drug resistant strains of bacteria.
Shares in Summit were trading up 1.8% at 7.25 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L